• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Daicel (TSE:4202) Stock Faces Margin Pressure Behind A 37.3x P/E

    Simply Wall St·08/01/2026 23:10:51
    语音播报

    Daicel stock closed at ¥1,450.5 after a choppy week that left short term holders roughly flat. The headline from these Q1 numbers is simple. The company swung back to profit after a recent quarterly loss, yet the trailing net margin over the past year sits at only 1.7%. For a chemicals group carrying a P/E of 37.3x, that gap between price and current profitability is what matters.

    In the near term you are trading that tension. Over a multi year horizon the key question is whether the forecast earnings growth is enough to justify both that valuation and a dividend that is not well covered.

    Is Daicel a misunderstood opportunity at 37.3x P/E with a 1.7% net margin, or is the DCF upside signal sending mixed messages? Compare the market price to our detailed valuation analysis for Daicel

    Q1 2027 Earnings Summary

    • Revenue (Q1 2027 vs Q1 2026): ¥152,383 million vs. ¥139,270 million (up about 9%)
    • Net Income (Excl. Extra Items, Q1 2027 vs Q1 2026): ¥9,360 million vs. ¥9,620 million (slightly lower)
    • Basic EPS (Q1 2027 vs Q1 2026): ¥36.65 per share vs. ¥36.28 per share (broadly flat)
    • Trailing 12 Month Net Margin (Q1 2027 vs prior year): 1.7% vs. 7.4% a year earlier (margin compressed over the year)

    Prefer clear, visual charts instead of another wall of earnings tables and ratios? See Daicel's full valuation picture at a glance in our company report for Daicel.

    TSE:4202 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    TSE:4202 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Daicel earnings and the case for cautious optimism

    For investors leaning positive on Daicel, the latest quarter offers some support. Revenue of ¥152,383 million is higher than the ¥139,270 million seen a year earlier, which fits the idea of a broad, resilient advanced materials platform. Basic EPS is broadly unchanged at ¥36.65 versus ¥36.28. That suggests Daicel is at least holding earnings per share while absorbing portfolio complexity and mixed end markets. For a diversified chemicals group, this combination of higher top line and steady per share earnings leans toward a restrained but still constructive interpretation.

    Daicel margin pressure and income quality concerns

    The more cautious view on Daicel finds real support in profitability. Trailing 12 month net margin is now 1.7%, compared with 7.4% a year earlier. That is a sharp compression for a business that investors often see as a dependable industrial. Net income excluding extra items is slightly lower at ¥9,360 million versus ¥9,620 million despite higher revenue, which hints at cost or mix pressure. The swing back to profit in the latest quarter is encouraging, but the weaker margin trend keeps concerns around earnings quality and dividend cover very much alive.

    Access the surface level consensus and then see where the models quietly diverge on Daicel's revenue, margins and EPS trajectory by checking the analyst estimates for Daicel.

    Stay Ahead With Simply Wall St

    If Daicel's 37.3x P/E against a 1.7% net margin has you weighing up the risk and potential, register for free with Simply Wall St and add it to your Watchlist so you can track price against fair value and wait for an entry point that suits you. Once you are invested, use the Portfolio Command Center to cut through market noise and keep focus on the updates that matter most to your holdings. For a broader view on Daicel and other stocks, tap into the Community to see how different investors are thinking about similar risks and opportunities. That way you can spot hidden catalysts and potential warning signs earlier and stay a step ahead of the market.

    Seeking Alternatives Beyond Daicel?

    Shortlists move fast and potential breakout stocks can gain momentum before you even notice. Scan these fresh ideas while they are still under the radar for now and consider them carefully.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.